For: | Wang XT, Guo W, Sun M, Han W, Du ZH, Wang XX, Du BB, Bai O. Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report. World J Clin Cases 2020; 8(14): 3122-3129 [PMID: 32775395 DOI: 10.12998/wjcc.v8.i14.3122] |
---|---|
URL: | https://www.wjgnet.com/2307-8960/full/v8/i14/3122.htm |
Number | Citing Articles |
1 |
Jingyu Song, Jie Liu, Dan Guo, Huibo Li, Shengjin Fan. Chidamide maintenance therapy after allo-HSCT in SET-NUP214 fusion positive T-ALL patients: A report of two cases. Transplant Immunology 2024; 87: 102119 doi: 10.1016/j.trim.2024.102119
|
2 |
|
3 |
Jia Liu, Jian Chen Fang, Lu Zhong. Effective treatment with programmed cell death protein‐1 antibody, chidamide and conventional chemotherapy for hepatosplenic γδ T‐cell lymphoma: A case report and literature review. Journal of Digestive Diseases 2022; 23(1): 50 doi: 10.1111/1751-2980.13068
|
4 |
Susann Schönefeldt, Tamara Wais, Marco Herling, Satu Mustjoki, Vasileios Bekiaris, Richard Moriggl, Heidi A. Neubauer. The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma. Cancers 2021; 13(24): 6212 doi: 10.3390/cancers13246212
|